论文部分内容阅读
KSR案修正了美国对专利非显而易见性的判断标准,运用“显而易见尝试”进行判断,而在Kubin案中显而“显而易见尝试”又被应用到了生物技术专利领域。对Kubin案的判决,将有可能使一些生物技术发明更难获得专利,可以肯定的是,技术进步和生物技术领域的知识会使更多的发明在这些进步的光亮下显得更为“显而易见”。
The KSR amended the United States’ judgment of the non-obviousness of the patent by using “obvious test”, whereas in the case of Kubin it was obvious that “obvious test” was applied to the area of biotechnology patents. The judgment in the Kubin case will make it harder for some biotechnological inventions to be patented, and it is certain that advances in technology and knowledge in the field of biotechnology will make more inventions more visible under the light of these advances. “ ”.